BioMarin Delays Resubmission, But Roctavian’s Rocky Road Winding Down

FDA Request Means Company Expects BLA By End Of September

 
• By Alaric DeArment
  
BioMarin said it would refile Roctavian by the end of September • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies